25 October 2021
Moscow, October 25, 2021 – Russian pharmaceutical company NovaMedica announces appointment of Timofey PETROV as the head of the R&D Center NovaMedica Innotech (subsidiary of NovaMedica).
Timofey has been working in the pharmaceutical industry for more than 20 years, and for 15 of them was employed at management positions in development and pharmaceutical production at such manufacturing companies as Rapharma JSC, Pharm-Sintez CJSC and Pharmcontract Group of Companies. He graduated from the Academician Pavlov Ryazan Medical University with a degree in Medical Care and from the S.Y. Witte Moscow University, Department of Economics. Timofey has an Executive MBA from the Moscow School of Management Skolkovo.
Elena Litvinova, Director General of NovaMedica:
We are glad to welcome the new leader of NovaMedica Innotech! I am convinced that Timofey Petrov is the right manager to take Innotech to a leading position in the Russian R&D and contract manufacturing market. I wish Timofey and the employees of NovaMedica Innotech to achieve perfect understanding and work as a well-knit team to meet new and interesting challenges”.
Timofey Petrov, Director General of the R&D Center NovaMedica Innotech:
”I am grateful to the management and shareholders of NovaMedica for having confidence in me, and I will try to justify it through new achievements of NovaMedica Innotech in research and manufacturing. A huge amount of work has been done in the four years since the creation of Innotech. I see the strategy of our further development in increasing the company’s competitiveness in the market by expanding the portfolio of technologies, which we are able to handle. I am sure that together with the professional team of Innotech we will be successful!”
NovaMedica Innotech is a 100% subsidiary of NovaMedica, a project of Rusnano, a Skolkovo resident, a rapidly developing Russian pharmaceutical R&D center opened in April 2017 at Technopolis Moscow. NovaMedica Innotech specializes in development, introduction and manufacturing of innovative, competitive and effective drug products.Print
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world
15 December 2022
In April 2023 drugs worth of 54.3 billion rubles were produced in Russia
09 June 2023
In Russia, child mortality is declining, while life expectancy is growing
09 June 2023
How can biopharma strengthen its resilience?
08 June 2023
Sergey Glagolev: Foreign companies are interested in conducting clinical trials in Russia
08 June 2023